Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544857 | 0.85 | TDP1 (0.54) | ALDH1A1POLBROCK1MKNK1MKNK2 | |
| SCHEMBL145442 | 0.85 | TDP1 (0.54) | ALDH1A1POLBROCK1MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL11255423 | 0.83 | TDP1 (0.52) | ALDH1A1POLBROCK1MKNK1MKNK2 | |
| Quinoline SCHEMBL28089948 | 0.79 | ALDH1A1 (0.85) | ALDH1A1POLBTDP1HTTKDM4E | |
| Pyridine SCHEMBL29278732 | 0.79 | POLB (0.47) | POLBROCK1MKNK1MKNK2TDP1 | |
| Quinoline SCHEMBL28089947 | 0.77 | ALDH1A1 (0.81) | ALDH1A1POLBTDP1HTTKDM4E | |
| Quinoline SCHEMBL15153044 | 0.77 | HTT (0.74) | ALDH1A1POLBHTTKDM4ESMN1; SMN2 | |
| Quinoline SCHEMBL2058675 | 0.77 | ALDH1A1 (0.90) | ALDH1A1POLBTDP1HTTKDM4E | |
| Quinoline SCHEMBL27941216 | 0.77 | ALDH1A1 (0.90) | ALDH1A1POLBTDP1HTTKDM4E | |
| Quinoline SCHEMBL29822171 | 0.77 | ALDH1A1 (1.00) | ALDH1A1POLBTDP1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875616-B2 | using 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or imatinib; type I and type II diabetes | HAEGERKVIST ROBERT PER | 2011-01-25 | — | — | US | disclosed |
| US-20080234285-A1 | Combination of Organic Compounds | FELDMAN DAVID LOUIS | 2008-09-25 | — | — | US | disclosed |
| US-20080070922-A1 | Combination of Organic Compounds | BURKEY BRYAN | 2008-03-20 | — | — | US | disclosed |
| CN-100372537-C | Use of tyrosine kinase inhibitors in the treatment of diabetes | PER HOGERKVIST ROBERT (SE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1802308-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | HAEGERKVIST ROBERT P | 2007-03-29 | — | — | US | disclosed |
| CN-1917865-A | Combinations of organic compounds | NOVARTIS AG (CH) | 2007-02-21 | — | — | CN | disclosed |
| WO-2006124544-A2 | USE OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| EP-1708691-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| CN-1794995-A | Use of tyrosine kinase inhibitors in the treatment of diabetes | HOGERKVIST ROBERT PER (SE) | 2006-06-28 | — | — | CN | disclosed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| EP-1631291-A2 | USE OF TYROSINE KINASE INHIBITORS TO TREAT DIABETES | Hägerkvist, Robert P. (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005070432-A1 | USE OF PDGF-R TK INHIBITORS FOR THE TREATMENT OF MYOCARDITIS AND ITS COMPLICATIONS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070406-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2004105763-A2 | USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES | HAEGERKVIST ROBERT PER (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070922-A1 | Combination of Organic Compounds | GIPR, IRS1, IGF1R | ALDH1A1 448/4885POLB 962/4885ROCK1 1950/4885 |
| US-20080234285-A1 | Combination of Organic Compounds | REN, PDGFRB, PDGFRA | ALDH1A1 457/4885POLB 1155/4885ROCK1 213/4885 |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | ABL2, PDGFRA, ABL1 | ALDH1A1 1097/4885POLB 4057/4885ROCK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.